Richard Whitley to Genetic Therapy
This is a "connection" page, showing publications Richard Whitley has written about Genetic Therapy.
Connection Strength
0.991
-
Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes. 2001 Mar; 8(1):17-22.
Score: 0.167
-
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998 Jan; 5(1):121-30.
Score: 0.135
-
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11313-8.
Score: 0.124
-
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May; 22(5):1048-55.
Score: 0.103
-
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012 May; 86(9):5304-13.
Score: 0.090
-
Oncolytic HSV-1 for the treatment of brain tumours. Herpes. 2006 Nov; 13(3):66-71.
Score: 0.062
-
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005 Apr; 12(4):359-68.
Score: 0.056
-
Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect. 2002 Sep; 8(9):551-63.
Score: 0.046
-
Herpes simplex viruses: is a vaccine tenable? J Clin Invest. 2002 Jul; 110(2):145-51.
Score: 0.046
-
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 2002 Jan; 9(1):75-80.
Score: 0.044
-
Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol. 2000 Jan-Feb; 10(1):17-30.
Score: 0.039
-
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene. 2019 08; 38(34):6159-6171.
Score: 0.037
-
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A. 1995 Feb 28; 92(5):1411-5.
Score: 0.028
-
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol. 2005 Jul; 7(3):213-24.
Score: 0.014